Mani Foroohar, an analyst from Leerink Partners, maintained the Buy rating on RegenXBio (RGNX – Research Report). The associated price target remains the same with $24.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mani Foroohar has given his Buy rating due to a combination of factors that highlight RegenXBio’s promising pipeline and financial stability. The company is making significant progress with its RGX-202 program for Duchenne muscular dystrophy, with over half of the patients already enrolled in the study and expectations for a commercial launch in 2027. This progress is complemented by the anticipated approval of RGX-121 for MPS II, which could further bolster the company’s market position.
Additionally, RegenXBio’s financial health appears robust, with sufficient cash reserves to fund operations into the second half of 2026, excluding potential milestones. The ongoing developments in their pipeline, such as the pivotal study for Sura-vec in wet AMD, also contribute to the positive outlook. These factors collectively support the Buy rating, reflecting confidence in the company’s strategic direction and potential for future growth.
In another report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock with a $24.00 price target.
RGNX’s price has also changed moderately for the past six months – from $10.490 to $7.970, which is a -24.02% drop .